Business Wire

Al-Falih Set to Attend Top Global Gathering of Energy Leaders

Del

Khalid Al-Falih, Saudi Arabia's Minister of Energy, Industry and Mineral Resources, and Amin Nasser, CEO of Saudi Aramco, will speak at the World Energy Congress to be held in Istanbul on 09-13 October.

The World Energy Congress is the most inclusive global energy event and the first since COP21. It brings together all nations, all forms of energy and all stakeholders in a neutral environment.

Al-Falih joins the industry’s elite at the Congress, including BP’s Bob Dudley, Gazprom’s Alexey Miller and EDF’s Jean-Bernard Lévy. Additionally, top executives from Royal Dutch Shell, GE, Total, ENGIE, VNG, DESFA, and China National Nuclear will be speaking at the Congress on major issues facing the energy industry.

Other speakers include representatives from intergovernmental and international organizations, including the EU, the IEA and the WWF, as well as ministers from Iran, Iraq, UAE, Jordan, Germany, Switzerland, Algeria, Nigeria and Uruguay, among others.

With the notion that security is key at such a high-level gathering, the World Energy Congress has appointed The Soufan Group to undertake a comprehensive analysis of the extensive security preparations underway for the event.

Murat Mercan, Chair of the Organising Committee for the 2016 World Energy Congress said: “Khalid Al-Falih’s attendance once again underlines the calibre of our 260 confirmed speakers - it is a “who’s who” of the entire energy sector. The event will be a crucial gathering to set the agenda for the energy landscape for years to come. We are also delighted to appoint The Soufan Group with their outstanding expertise to work for the safety of our delegates, staff and exhibitors.

Ali Soufan, CEO of The Soufan Group noted: “We are honoured to be appointed to undertake an assessment of the security preparations underway for the 2016 World Energy Congress. One of the most prestigious events in the energy calendar, it is a truly market-leading event attracting the world’s most influential industry leaders. We will work tirelessly with the organisers to ensure that best safety standards and practices are in place during the Congress.”

ABOUT THE WORLD ENERGY CONGRESS

The triennial World Energy Congress is the World Energy Council’s global flagship event, the premier international, multi-energy forum to better understand energy issues and solutions from a global perspective.

The World Energy Congress has gained recognition since the first event in 1924 as the premier global forum for industry leaders to debate solutions to energy issues, display their technologies and explore business opportunities.

For more information and to register, visit: http://www.wec2016istanbul.org.tr/

Follow @WECongress for regular updates.

ABOUT THE SOUFAN GROUP

The Soufan Group is an international strategic advisory firm that focuses on global security issues. Headquartered in New York, and with offices in Chicago, London, Doha and Singapore and operations in the Middle East, Asia, and Africa, The Soufan Group provides management consulting, business intelligence, policy analysis, risk assessment, technical support and training services. The team to work on WEC 2016 includes internationally recognized law enforcement and security professionals with backgrounds in various national security, law enforcement and intelligence organizations, and extensive experience in counterterrorism operations and investigations, major event security, crisis management, executive protection, cyber-security, and hostage rescue.

Contact information

World Energy Congress
Media enquiries:
Soufan Group:
Timothy Rhein
timothy.rhein@soufangroup.com
or
Congress Organising Committee:
Roisin Miller
+44 (0) 203 861 3952
worldenergycongress@grayling.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom